U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C19H21N3O.C4H6O6
Molecular Weight 764.8675
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOLPIDEM TARTRATE

SMILES

Cc1ccc(cc1)-c2c(CC(=O)N(C)C)n3cc(C)ccc3n2.Cc1ccc(cc1)-c2c(CC(=O)N(C)C)n3cc(C)ccc3n2.[C@@]([H])([C@]([H])(C(=O)O)O)(C(=O)O)O

InChI

InChIKey=VXRDAMSNTXUHFX-CEAXSRTFSA-N
InChI=1S/2C19H21N3O.C4H6O6/c2*1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19;5-1(3(7)8)2(6)4(9)10/h2*5-10,12H,11H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.087
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C19H21N3O
Molecular Weight 307.3903
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Zolpidem interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem in vitro binds the BZ1 receptor preferentially with a high affinity ratio of the α1/α5 subunits. This selective binding of zolpidem on the BZ1 receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep in human studies of zolpidem tartrate at hypnotic doses.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMBIEN

Approved Use

Ambien (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Ambien has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14)

Launch Date

724464000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
121 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
59 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
26 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.5%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.5%
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Other AEs: Psychiatric symptom, Gastrointestinal disorder (NOS)...
Other AEs:
Psychiatric symptom (6 patients)
Gastrointestinal disorder (NOS) (6 patients)
Nervous system disorder NOS (5 patients)
Sources:
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
unhealthy, 68 years
Health Status: unhealthy
Age Group: 68 years
Sex: F
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Drowsiness, Vertigo...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1.1%)
Vertigo (0.8%)
Amnesia (0.5%)
Nausea (0.5%)
Headache (0.4%)
Fall (0.4%)
Sources:
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Drowsiness, Dizziness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (0.5%)
Dizziness (0.4%)
Headache (0.5%)
Nausea (0.6%)
Vomiting (0.5%)
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 10 patients)
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Somnolence, Coma...
AEs leading to
discontinuation/dose reduction:
Somnolence (100%)
Coma (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nervous system disorder NOS 5 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Gastrointestinal disorder (NOS) 6 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Psychiatric symptom 6 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Death grade 5, 1 patient
Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
unhealthy, 68 years
Health Status: unhealthy
Age Group: 68 years
Sex: F
Sources:
Fall 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Amnesia 0.5%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 0.5%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vertigo 0.8%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Drowsiness 1.1%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Dizziness 0.4%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Drowsiness 0.5%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 0.5%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vomiting 0.5%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 0.6%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Death grade 5, 10 patients
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Coma 1 patient
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Somnolence 100%
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: A single-dose interaction study with zolpidem tartrate 10 mg and rifampin (CYP3A4 inducer) 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), Cmax (-58%), and T1/2 (-36 %) of zolpidem together
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Development and modulation of GABA(A) receptor-mediated neurotransmission in the CA1 region of prenatally protein malnourished rats.
2001
[Correction of sleep disorders and efficacy of antihypertensive monotherapy in elderly patients: use of ivadal].
2001
Measurement of cerebral perfusion after zolpidem administration in the baboon model.
2001
Alternative medicine. Achieving balance between herbal remedies and medical therapy.
2001 Aug
Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.
2001 Aug
Comparative effects of melatonin, zolpidem and diazepam on sleep, body temperature, blood pressure and heart rate measured by radiotelemetry in Wistar rats.
2001 Aug
Zolpidem abuse.
2001 Aug
Zolpidem use and hip fractures in older people.
2001 Dec
Assessing the effects of an intervention by a pharmacist on prescribing and administration of hypnotics in nursing homes.
2001 Dec
Delirium associated with zolpidem.
2001 Dec
[Zolpidem: the risk of tolerance and dependence according to case reports, systematic studies and recent molecularbiological data].
2001 Dec
Diminished allopregnanolone enhancement of GABA(A) receptor currents in a rat model of chronic temporal lobe epilepsy.
2001 Dec 1
Functional analysis of GABA(A) receptors in nucleus tractus solitarius neurons from neonatal rats.
2001 Dec 7
Hypnotic dependence: zolpidem and zopiclone too.
2001 Feb
Acute zolpidem overdose leading to coma and respiratory failure.
2001 Jul
[Homeopathic specialties as substitutes for benzodiazepines: double-blind vs. placebo study].
2001 Jul-Aug
A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
2001 Jun
gamma-Aminobutyric acid(A) receptor subunit expression predicts functional changes in hippocampal dentate granule cells during postnatal development.
2001 Jun
A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia.
2001 May-Jun
Treatment of insomnia in hospitalized patients.
2001 Nov
Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation.
2001 Nov
Arousal from a semi-comatose state on zolpidem.
2001 Oct
Prevalence between different alpha subunits performing the benzodiazepine binding sites in native heterologous GABA(A) receptors containing the alpha2 subunit.
2001 Oct
Insomnia: therapeutic approach.
2001 Sep
Potency of positive gamma-aminobutyric acid(A) modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys.
2001 Sep
Zolpidem in restless legs syndrome.
2002
Tolerability of hypnosedatives in older patients.
2002
Hallucinations and Zolpidem.
2002 Aug
Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.
2002 Aug 1
The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem.
2002 Aug 15
Discriminative stimulus effects of benzodiazepine (BZ)(1) receptor-selective ligands in rhesus monkeys.
2002 Feb
Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem.
2002 Feb
Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors.
2002 Feb 15
Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome.
2002 Feb 26
Fibromyalgia: patient perspectives on symptoms, symptom management, and provider utilization.
2002 Jan
Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study.
2002 Jan
Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia.
2002 Jan
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography.
2002 Jul
[Abuse, tolerance and dependence of zolpidem: three case reports].
2002 Jul-Aug
Zolpidem in progressive supranuclear palsy.
2002 Mar
Sleep disorders and daytime sleepiness in state police shiftworkers.
2002 Mar-Apr
Clinical syndrome associated with zolpidem ingestion in dogs: 33 cases (January 1998-July 2000).
2002 Mar-Apr
Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.
2002 May
Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons.
2002 Oct
Functional characterization of GABA(A) receptors in neonatal hypothalamic brain slice.
2002 Oct
Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use.
2002 Oct
Relative picrotoxin insensitivity distinguishes ionotropic GABA receptor-mediated IPSCs in hippocampal interneurons.
2002 Sep
GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem.
2002 Sep
Mechanisms of anabolic androgenic steroid modulation of alpha(1)beta(3)gamma(2L) GABA(A) receptors.
2002 Sep
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes.
2002 Sep 13
Patents

Patents

Sample Use Guides

Dosage in Adults: the recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness. The total dose of AMBIEN (zolpidem tartrate) should not exceed 10 mg once daily immediately before bedtime. Ambien should be taken as a single dose and should not be readministered during the same night.
Route of Administration: Oral
Human embryonic kidney (HEK) 293 cells stably expressing recombinant α1β2γ2s GABA(A) receptors were exposed to zolpidem (1 and 10 μmol/L) for short-term (2 h daily for 1, 2, or 3 consecutive days) or long-term (continuously for 48 h). Radioligand binding studies were used to determine the parameters of [(3)H]flunitrazepam binding sites. A single (2 h) or repeated (2 h daily for 2 or 3 d) short-term exposure to zolpidem affected neither the maximum number of [(3)H]flunitrazepam binding sites nor the affinity. In both control and short-term zolpidem treated groups, addition of GABA (1 nmol/L-1 mmol/L) enhanced [(3)H]flunitrazepam binding in a concentration-dependent manner. The maximum enhancement of [(3)H]flunitrazepam binding in short-term zolpidem treated group was not significantly different from that in the control group. In contrast, long-term exposure to zolpidem resulted in significantly increase in the maximum number of [(3)H]flunitrazepam binding sites without changing the affinity. Furthermore, long-term exposure to zolpidem significantly decreased the ability of GABA to stimulate [(3)H]flunitrazepam binding.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:05:55 UTC 2021
Edited
by admin
on Fri Jun 25 21:05:55 UTC 2021
Record UNII
WY6W63843K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOLPIDEM TARTRATE
EP   HSDB   JAN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
(2R,3R)-2,3-DIHYDROXYSUCCINIC ACID - N,N-DIMETHYL-2-(6-METHYL-2-(4-METHYLPHENYL)IMIDAZO(1,2-A)PYRIDIN-3-YL)ACETAMIDE (1:2)
Common Name English
AMBIEN
Brand Name English
STILNOX
Brand Name English
ZOLPIDEM TARTRATE [MART.]
Common Name English
SL-80.0750
Code English
N,N,6-TRIMETHYL-2-P-TOLYL-IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE L-(+)-HEMITARTRATE (2:1)
Common Name English
ZOLPIDEM TARTRATE CIV
USP-RS  
Common Name English
ZOLPIDEM HEMITARTRATE
Common Name English
N,N,6-TRIMETHYL-2-P-TOLYLIMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE L-(+)-TARTRATE (2:1)
Common Name English
ZOLPIDEM L-(+)-HEMITARTRATE [MI]
Common Name English
MYSLEE
Brand Name English
ZOLPIDEM TARTRATE [ORANGE BOOK]
Common Name English
INTERMEZZO
Brand Name English
IVADAL
Brand Name English
ZOLPIDEM TARTRATE [EP MONOGRAPH]
Common Name English
NIOTAL
Brand Name English
ZOLPIDEM TARTRATE [USP MONOGRAPH]
Common Name English
ZOLPIDEM TARTRATE [JAN]
Common Name English
ZOLPIDEM TARTRATE [USAN]
Common Name English
ZOLPIDEM TARTRATE [WHO-DD]
Common Name English
SL-80.0750-23N
Code English
SL 80.0750-23N
Code English
ZOLPIDEM TARTRATE [HSDB]
Common Name English
STILNOCT
Brand Name English
ZOLPIDEM TARTRATE CIV [USP-RS]
Common Name English
TOVALT
Brand Name English
IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE, N,N,6-TRIMETHYL-2-(4-METHYLPHENYL)-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (2:1)
Common Name English
ZOLPIDEM L-(+)-HEMITARTRATE
MI  
Common Name English
ZOLPIDEM TARTRATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29756
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
Code System Code Type Description
RXCUI
221183
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY RxNorm
HSDB
7045
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
EVMPD
SUB05192MIG
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL911
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
MERCK INDEX
M11661
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY Merck Index
EVMPD
SUB127297
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
NCI_THESAURUS
C29553
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
FDA UNII
WY6W63843K
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
USP_CATALOG
1724907
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY USP-RS
DRUG BANK
DBSALT001047
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
PUBCHEM
441338
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
CAS
99294-93-6
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY